150 µg Corifollitropin Alfa + 200 IU RecFSH/Follitropin beta (Days 1 to 7) + Placebo for Corifollitropin Alfa + Placebo for RecFSH/Follitropin beta + 200 IU RecFSH/Follitropin beta (Days 8 to hCG) + Ganirelix + hCG + Progesterone

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

In Vitro Fertilization

Conditions

In Vitro Fertilization

Trial Timeline

Apr 19, 2006 → May 31, 2009

About 150 µg Corifollitropin Alfa + 200 IU RecFSH/Follitropin beta (Days 1 to 7) + Placebo for Corifollitropin Alfa + Placebo for RecFSH/Follitropin beta + 200 IU RecFSH/Follitropin beta (Days 8 to hCG) + Ganirelix + hCG + Progesterone

150 µg Corifollitropin Alfa + 200 IU RecFSH/Follitropin beta (Days 1 to 7) + Placebo for Corifollitropin Alfa + Placebo for RecFSH/Follitropin beta + 200 IU RecFSH/Follitropin beta (Days 8 to hCG) + Ganirelix + hCG + Progesterone is a pre-clinical stage product being developed by Organon for In Vitro Fertilization. The current trial status is completed. This product is registered under clinical trial identifier NCT00702273. Target conditions include In Vitro Fertilization.

Hype Score Breakdown

Clinical
3
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00702273Pre-clinicalCompleted